Arnódi-Mészáros Beata

Dr. Arnódi-Mészáros Beata


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TSTibor Gabor Szántó
Tibor Gabor Szántó
FAFeher Adam
Feher Adam
EKEva Korpos
Eva Korpos
AGAdrienn Gyöngyösi
Adrienn Gyöngyösi
JKJudit Kállai
Judit Kállai
ZVZoltan Varga
Zoltan Varga
5-chloro-2-guanidinobenzimidazole (ClGBI), a small-molecule guanidine derivative, is a known effective inhibitor of the voltage-gated proton (H+) channel (HV1, Kd ≈ 26 μM) and is widely used both in ion channel research and functional biological assays. However, a comprehensive study of its ion channel selectivity determined by electrophysiological methods has not been published yet. The lack of selectivity may lead to incorrect conclusions regarding the role of hHv1 in physiological or pathophysiological responses in vitro and in vivo. We have found that ClGBI inhibits the proliferation of lymphocytes, which absolutely requires the functioning of the KV1.3 channel. We, therefore, tested ClGBI directly on hKV1.3 using a whole-cell patch clamp and found an inhibitory effect similar in magnitude to that seen on hHV1 (Kd ≈ 72 μM). We then further investigated ClGBI selectivity on the hKV1.1, hKV1.4-IR, hKV1.5, hKV10.1, hKV11.1, hKCa3.1, hNaV1.4, and hNaV1.5 channels. Our results show that, besides HV1 and KV1.3, all other off-target channels were inhibited by ClGBI, with Kd values ranging from 12 to 894 μM. Based on our comprehensive data, ClGBI has to be considered a non-selective hHV1 inhibitor; thus, experiments aiming at elucidating the significance of these channels in physiological responses have to be carefully evaluated.

Verified
Journal Article
Open access
PDF file
ABArnódi-Mészáros Beata
Arnódi-Mészáros Beata
ACAgota Csoti
Agota Csoti
TSTibor Gabor Szántó
Tibor Gabor Szántó
ATAndrea Telek
Andrea Telek
KKKatalin Kovács
Katalin Kovács
Gyorgy PanyiGyorgy Panyi
Gyorgy Panyi
The hEag1 (Kv10.1) K+ channel is normally found in the brain, but it is ectopically expressed in tumor cells, including osteosarcoma. Based on the pivotal role of ion channels in osteogenesis, we tested whether pharmacological modulation of hEag1 may affect osteogenic differentiation of osteosarcoma cell lines. Using molecular biology (RT-PCR), electrophysiology (patch-clamp) and pharmacology (astemizole sensitivity, IC50 = 0.135 μM) we demonstrated that SaOS-2 osteosarcoma cells also express hEag1 channels. SaOS-2 cells also express to KCa1.1 K+ channels as shown by mRNA expression and paxilline sensitivity of the current. The inhibition of hEag1 (2 μM astemizole) or KCa1.1 (1 mM TEA) alone did not induce Ca2+ deposition in SaOS-2 cultures, however, these inhibitors, at identical concentrations, increased Ca2+ deposition evoked by the classical or pathological (inorganic phosphate, Pi) induction pathway without causing cytotoxicity, as reported by three completer assays (LDH release, MTT assay and SRB protein assay). We observed a similar effect of astemizole on Ca2+ deposition in MG-63 osteosarcoma cultures as well. We propose that the increase in the osteogenic stimuli-induced mineral matrix formation of osteosarcoma cell lines by inhibiting hEag1 may be a useful tool to drive terminal differentiation of osteosarcoma.

1 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JBJesús Angel Borrego
Jesús Angel Borrego
ABArnódi-Mészáros Beata
Arnódi-Mészáros Beata
TSTibor Gabor Szántó
Tibor Gabor Szántó
TRTeklu Teshome Russo
Teklu Teshome Russo
EKEva Korpos
Eva Korpos
FPFerenc Papp
Ferenc Papp
The voltage-gated proton channel (Hv1) selectively transports protons (H+) across biological membranes in response to membrane potential changes. Hv1 is assembled as a dimer, and unlike most voltage-gated ion channels, it lacks a traditional central pore domain; instead, the voltage-sensing domain (VSD) of each monomer facilitates proton conduction via a hydrogen-bond network. Hv1 is widely expressed in various human cell types (e.g., immune cells, sperm, etc.) including tumor cells. In tumor cells, the accumulation of acidic intermediates generated by glycolysis under hypoxic conditions or ROS production leads to significant cytosolic acidification. Hv1 can remove protons from the cytosol rapidly, contributing to the adaptation of the cells to the tumor microenvironment, which may have significant consequences in tumor cell survival, proliferation, and progression. Therefore, Hv1 may be very promising not only as a tumor marker but also as a potential therapeutic target in oncology. Molecules that modulate the proton flux through Hv1 can be divided into two broad groups: inhibitors and activators. Hv1 inhibitors can be simple ions, small molecules, lipids, and peptides. In contrast, fewer Hv1 activators are known, including albumin, NH29, quercetin, and arachidonic acid. The mechanism of action of some inhibitors is well described, but not all. Hv1 modulation has profound effects on cellular physiology, especially under stress or pathological conditions, like cancer and inflammation. The therapeutic application of selective Hv1 inhibitors or activators could be a very promising strategy in the treatment of several serious diseases.